

Leiomyosarcoma (LMS) areis a rare tumors of the small intestine, which arises from the musculalris mucosa or muscularis propria. The most common site of LMS occurrence in the small intestine is the jejunum, followed by the ileum and then-duodenum. The Its common presentations manifestations include abdominal mass, abdominal pain, and or overt gastrointestinal bleeding. They LMS are mainly seen occurs in the 6th decade of life, with slight male preponderance.

The Ppreoperative diagnosis of small intestinal tumors is difficult, especially in terms of differentiating between benign and malignant tumors. For LMS in small intestine, <u>A</u> recent review of literature review revealed that computed tomography (CT)- and magnetic resonance (MRI)-enterography and enteroclysis are good optionsmodalities for the assessment of LMS in the small intestine. Cases of sS uperficial lesions, which can be missed by both CT and MRI imaging, can however be detected by water capsule endoscopy, with a detection rate of around approximately 80%.

Histologically, LMS resembles like gastrointestinal stromal tumorGIST, however, they are it is negative for CD117 and CD34 negative by immunohistochemistry and positive for smooth muscle antigen actin (SMA) and desmin on immunohistochemistry. When the size of LMS these tumors are is more than 5 cm, they it commonly spreads hematogenously to the liver (65%), other gastrointestinalGI organs (15%), and the lungs (4%). It also has the capability to can also spread via the lymphatics system (13%) or via peritoneal route (18%). The only effective treatment for LMS in the small intestine LMS-is surgery. The primary tumor should be excised radically, including a with wide resection of the mesentry. Response The response of LMS to chemotherapy is doubtful unknown, and there is no role for radiotherapy does not play a role in treatment. Therefore, if possible, metastasectomy; if possible, should be

www.enago.com | www.enago.jp | www.enago.com.tr | www.enago.com.br | www.enago.de | www.enago.tw | www.enago.cn | www.enago.co.kr | www.enago.ru **Comment [A1]:** The definite article "the" is used to denote specificity. Here, "the" is required as a specific organ is being referred to.

Comment [A2]: A nonrestrictive clause is a clause that adds additional or nonessential information to a sentence. Such clauses are usually separated by commas. Here, as the clause provides additional information about detection of superficial lesions, it is separated by a comma.

Comment [A3]: In general, terms that are used only once in the manuscript need not be abbreviated.

All material in this document is the intellectual property of Crimson Interactive Pvt. Ltd. The use of information and content in this document in whole or in part is forbidden unless express permission has been given in writing by Crimson Interactive Pvt. Ltd.



considered.- Large phase II and III studies<u>trials</u> involving the combination of <u>combining</u> docetaxel and gemcitabine <u>have reported yielded</u> impressive response rates <u>for in</u>-LMSs (mostly of uterine origin). However, <u>some studies others were have</u> not <u>been</u> able to confirm the efficacy of this combination. Recently, trabectedin showed response rates <u>of</u> up to 56% <u>for in-LMSs</u>, and <u>it has</u> appeared to be <u>especially-particularly</u> useful <u>against in</u> far-advanced and metastatic LMSs after failure of the combination of anthracyclines and ifosfamide.

All material in this document is the intellectual property of Crimson Interactive Pvt. Ltd. The use of information and content in this document in whole or in part is forbidden unless express permission has been given in writing by Crimson Interactive Pvt. Ltd.

www.enago.com | www.enago.jp | www.enago.com.tr | www.enago.com.br | www.enago.de | www.enago.tw | www.enago.cn | www.enago.co.kr | www.enago.ru